Figure 6
The peptide PB1491-515 can inhibit the activity of influenza virus RNA dependent RNA polymerase in vivo and in vitro effectively.
(A) The inhibitory effects of PB1491-515-GFP to activity of influenza virus RdRP in influenza A virus minireplicon systems. (B) The inhibitory effects of synthesized peptide PB1491-515-TAT to virus (A/Quail/HK/G1/97) infection. A549 cells were treated with indicated synthesized peptides before and after virus infection. The activity detected with samples containing PX-TAT was set to 100% after subtracting background of uninfected samples. (C) In vitro ApG primed transcription activity of PB2-TAP purified influenza A virus polymerase with synthesized peptides PX-TAT or PB1491-515-TAT at indicated concentrations (μM). TP means transcription products. (D) 3' vRNA promoter binding activity of influenza virus RdRP after adding indicated peptides. The position of RNA cross-linked polymerase is indicated. Sample without polymerase (no protein) is used as negative control.
